STADA - Caring for People's Health
A message from Peter Goldschmidt, CEO
STADA’s 13,000 employees around the world can be extremely proud of the group’s performance in 2022.
We were able to supply more than one billion units to patients, delivering on our purpose of Caring for People’s Health as a Trusted Partner. Being a reliable supplier of medicines and healthcare products is reflected in our double-digit sales and profit growth.
This progress was particularly impressive given the considerable geopolitical and economic challenges we faced in 2022. The ongoing war in Ukraine continues to directly impact the lives of millions of citizens, including many of our STADA colleagues, to whom we are offering all the support we can as part of our broader humanitarian aid.
STADA has outperformed the market in terms of sustainable growth
Thanks to our unique growth culture and highly engaged employees, we were able to realize our vision again in 2022 to be the partner of choice in Consumer Healthcare, Generics, and Specialty Pharmaceuticals and outperform the industry in terms of growth and profitability.
Boris Döbler
Chief Financial Officer
"Caring for People’s Health” starts with STADA’s employees
STADA’s key to success lies in its highly engaged team and its culture. The four company values – Agility, Entrepreneurship, Integrity and One STADA – form the basis for all decisions made and actions taken by STADA employees.
As part of STADA’s fifth strategic priority – growth culture – the company strives for a productive team that is highly skilled and engaged. Being the best team in the industry is only possible if employees, their inclusion, and their continued development are STADA’s number one consideration, in the spirit of “Caring for People’s Health as a Trusted Partner.”
The diversity of our employees, and the fact that each brings their unique abilities to the table every day, is a hallmark of our growth culture. I firmly believe this is the decisive factor that distinguishes us from the competition.
Simone Berger
Chief Human Resources Officer
STADA among the top ten percent of the most sustainable pharmaceutical companies
STADA continues to make great strides in implementing sustainability goals, as confirmed by an independent assessment. Based on a comprehensive framework of more than 70 management indicators, the leading environmental, social and governance (ESG) rating organization, Sustainalytics, announced a further improvement to the company’s ESG risk rating in December 2022.
Consistent with its own areas of business, company purpose, and values, STADA supports the implementation of the following SDGs:
We are integrating sustainable aspects more systematically into our business processes. We must continue this journey by identifying opportunities for improvement.
Miguel Pagan Fernandez
Chief Technical Officer
Every one of us constantly aspires to make a positive impact on the world and those around us by the way we work and live.
Christoph Dengler
Head of Global Legal
STADA generates €1.6 billion with local brands
STADA is the fourth-largest consumer healthcare company in Europe and markets products internationally in all relevant healthcare categories. This is now the largest sector by sales in the company.
As a diverse international player with a strong presence in various international markets, STADA is increasingly the go-to partner in the consumer healthcare industry. Recent acquisitions and product launches reinforce STADA’s position as a leading supplier and form an excellent basis for further growth.
Volker Sydow
Head of Global Consumer Healthcare
Affordable generics have been the backbone of STADA since 1895
Affordable generics are the backbone of the European healthcare system. STADA offers generic products in all essential product categories.
By providing the same active ingredients, often at a significantly lower price than the cost of original products, suppliers can offer patients affordable access to generic products for proven treatments of a variety of medical conditions and illnesses.
As a major player in the generics sector, STADA supports patient care with affordable medicines. This is especially true in Europe, where the company ranks as the fourth- largest manufacturer and supplier of generics in terms of sales.
Seven out of ten medicines prescribed in Europe are generic, but these account for only about 30 percent of all pharmaceutical expenditure.
As the fourth largest generics manufacturer, we strongly support patients and, of course, the healthcare systems of Europe, because generics are not just important for healthcare – they are essential for millions of people to have access to high-quality medical care.
Stephan Eder
Head of European Markets
Specialty pharmaceuticals on the rise
For STADA, the development and supply of specialty pharmaceuticals that have been inaccessible or only partially accessible to patients until now is a perfect addition to its purpose of “Caring for People’s Health as a Trusted Partner.” The goal is clear: to improve access to life-changing treatments for patients worldwide.
Specialty pharmaceuticals are becoming increasingly important in the pharmaceutical industry. These are medicines that are often used to treat chronic, severe, or rare diseases, and for which demand is considerable and increasing. This may include new formulations, combinations, or applications that bring additional benefits to well-known medicines. Specialty pharmaceuticals typically have complex aspects as regards manufacturing, prescription, distribution and administration.
Developing and manufacturing such specialty pharmaceuticals, and informing both doctor and patient about their application, require special expertise. STADA already has extensive experience in patient care across the entire treatment spectrum – from vitamins and food supplements to biologic therapies against cancer.
We will use our various medical, technical and commercial capabilities in the Specialty Pharmaceuticals sector to deliver both quality and value.
Bryan Kim
Head of Specialty
Through partnerships, STADA is establishing a sustainable specialty pipeline.
Yann Brun
Head of Global Legal, Head of Global Development, Portfolio, Regulatory and Business Development/Licensing
Position STADA as a long-term-superior growth leader
We drive our performance by connecting people – cross-functionally and cross-nationally. In 2023 and beyond, we continue to position STADA as a growth leader.
Frank Staud
Head of Global Corporate Communications
Position STADA’s growth journey externally
Drive STADA's culture through enhanced internal communication
Accelerate successful digital strategy
STADA Production sites – keep supplying medicines
STADA Annual Report 2022
